Skip to main content
. Author manuscript; available in PMC: 2019 Feb 27.
Published in final edited form as: Endocrine. 2016 Sep 23;54(3):768–777. doi: 10.1007/s12020-016-1083-6

Table 3.

Percentage of FKBP5 DNA methylation according to gcnotyping in CS patients and controls

All subjects (n = 64) CC genotype (n = 22) TC genotype (n = 34) TT genotype (n = 8) p p1 p2 p3
Intron2 Region2CpG-3 71.0 % (62.6–77) 70.8 % (55.2–78.3) 66.6 % (62.5–70.2) 0.01 0.02 ns ns
Intron7 CpG-5 77.7 % (72.2–89.6) 77.6 % (68.9–87.6) 74.2 % (60.2–76.4) 0.01 0.01 ns ns
CS patients (n = 32) CC genotype (n = 11) TC+TT genotypes (n = 21)
Intron 2 region 1 CpG-5 95.0 % (92.3–97.2) 93.5 % (82.5–95.8) - - - - 0.04

All subjects

p = significance between TT genotypes compared to CC genotypes

p1 = significance between TT genotypes compared to TC genotypes

p2 = significance between TC genotypes compared to CC genotypes

CS patients

P3 = significance between CS patients with the T allele (TTgenotypes + TC genotypes) compared to the patients without the T allele (CC genotypes)